Over at ScienceBlogs, Orac has put up an excellent post on the disturbing stem cell situation in Italy. This is a great, probing piece and I highly recommend it, but there’s more going on there too that is worth taking a look at including social media stuff. One of the other intriguing things about this […]
Stem cell clinic social media shenanigans exposed Read More »
Two emerging acronyms in the for-profit stem cell world that remain unknown to most academic stem cell scientists, but that are generating the most buzz are: SVF and CAL. These are two fat acronyms. What? These acronyms relate to adipose (fat) stem cell-based procedures. SVF stands for “stromal vascular fraction”. SVF is, for lack of
SVF & CAL are two fat stem cell acronyms generating a lot of buzz Read More »
The Korean-based stem cell biotech, RNL Bio, which also does business in the U.S. as RNL Bio and Human Biostar Inc, reportedly (seems to be a press release, PR) has filed an investigational new drug (IND) application with the Korean FDA (KFDA). The purpose of the application is to test the efficacy of autologous adult stem cells
For the second year in a row (see awards 2011), Advanced Cell Technology (ACT; stock symbol ACTC) is my stem cell biotech of the year. Their trials for different forms of macular degeneration (here and here and here) are progressing well and as a stem cell scientist I really appreciate the fact they are publishing their
Stem cell biotech of the year 2012: Advanced Cell Technology (ACTC) Read More »
One of the most exciting types of stem cells are mesenchymal stem cells or MSCs. Although there is some debate about these cells (e.g. I once heard Irv Weissman say at a meeting he wasn’t sure they really existed as such), a consensus would seem to be that they have great potential medical potential. Perhaps
Mapping global trends in MSC & stem cell clinical trials: unexpected findings Read More »
Chronic obstructive pulmonary disease (COPD) is a relatively common, often debilitating illness, which has a major impact on the people of the world. In the U.S. alone, COPD costs the country almost $50 billion a year not to mention untold suffering. Most of us know someone who has COPD. COPD is an umbrella term that
Stem cells for COPD including emphysema: are we there yet? Read More »
Autism affects millions of children in the U.S. alone; could stem cells for autism help? It is a perplexing spectrum of disorders with “autism” being an umbrella term for a host of related neurological illnesses. The negative impact of autism on our society transcends economics, but has been estimated at 10s of billions of dollars.
Stem cells for autism: are we there yet? Read More »
Where do things stand on the potential of stem cell treatments for multiple sclerosis (MS)? MS is an often devastating autoimmune disease in which the immune system attacks its own nervous system. More info can be found at the National MS website here. MS is a very serious health problem globally as about 400,000 people
Stem cell treatments for multiple sclerosis: where do things stand? Read More »
Clinicaltrials.gov is where you want to go for finding a certain clinical trial and studies. Note that this U.S. database Clinicaltrials.gov includes international trials. It is a very powerful tool! Check it out here to do your own searches. Also follow me on Twitter for all the latest info and expert analysis: http://twitter.com/pknoepfler and this patient’s
Tool to easily search for a stem cell clinical trial for your disease Read More »
Can stem cells treat the different forms of arthritis that plague 100s of millions of people across the globe? A couple years back I did a post in my disease focus series on the potential of stem cells to be used as treatments for osteoarthritis (OA). OA affects almost 30 million people in the U.S.
Stem cells for arthritis: are we there yet? Read More »